PillRx only · Solution · Oral
Topiramate
Brands: Eprontia · Topiramate
3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US3 NDCs
3 active makers
3 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 5 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$2.007
Latest avg · Jul 22, 2026
+85%
Since Dec 17, 2025
3
Active US suppliers
67%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
13K
Rx · 2026 Q1
2.9M
Units dispensed
-0%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it3 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Kesin Pharma Corporation | unknown | 3 | SUPPLYING |
| Azurity Pharmaceuticals, Inc. | unknown | 3 | SUPPLYING |
| Ascend Laboratories, LLC | unknown | 3 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Dec 8, 2023RECALLRecall (Class III): Eprontia (topiramate) oral solution, 25 mg/mL, 473 mL Bottle, Rx only, Manufactured for: Azurity Pharmaceuticals, Wobur…
Failed Impurities/Degradation Specifications: Out of specification Impurity C (4,5-desisopropylidene topiramate) result observed during routine stability testing at 18 months. — Recalling firm: Azurity Pharmaceuticals, Inc. — USA nationwide.